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Abstract 
Purpose: To document the current prostate brachytherapy practice across the UK and Ireland and compare with 
previously published audit results. 
Material and methods: Participants from 25 centers attending the annual UK & Ireland Prostate Brachytherapy 
Conference were invited to complete an online survey. Sixty-three questions assessed the center’s experience and 
staffing, clinician’s experience, clinical selection criteria and scheduling, number of cases per modality in the preced-
ing three years, low-dose-rate (LDR) pre- and post-implant technique and high-dose-rate (HDR) implant technique. 
Responses were collated, and descriptive statistical analysis performed. 
Results: Eighteen (72%) centers responded with 17 performing LDR only, 1 performing HDR only, and 6 perform-
ing both LDR and HDR. Seventy-one percent of centers have > 10 years of LDR brachytherapy experience, whereas 
71% centers that perform HDR brachytherapy have > 5 years of experience. Thirteen centers have 2 or more clinicians 
performing brachytherapy with 61% of lead consultants performing > 25 cases (LDR + HDR) in 2016. The number of 
implants (range), that includes LDR and HDR, performed by individual practitioners in 2016 was > 50 by 21%, 25-50 by 
38%, and < 25 by 41%. Eight centers reported a decline in LDR monotherapy case numbers in 2016. Number of center’s 
performing HDR brachytherapy increased in last five years. Relative uniformity in patient selection is noted, and LDR 
pre- and post-implant dosimetry adheres to published quality guidelines, with an average post-implant D90 of > 145 Gy 
in 69% of centers in 2014 and 2015 compared to 63% in 2016. The median CT/US volume ratios were > 0.9 ≤ 1.0 
(n = 4), > 1.0 ≤ 1.1 (n = 7), and > 1.1 (n = 2). 
Conclusion: There is considerable prostate brachytherapy experience in the UK and Ireland. An apparent fall in 
LDR case numbers is noted. Maintenance of case numbers and ongoing compliance with published quality guidelines 
is important to sustain high quality outcomes. 
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Purpose 
Low-dose-rate (LDR) permanent seed and high-dose-
rate (HDR) temporary source brachytherapy are well recog-
nized and effective treatment options for selected patients 
with localized prostate cancer of any risk group [1,2,3,4,5,6]. 
Brachytherapy as monotherapy or combination with ex-
ternal beam radiotherapy (EBRT) have demonstrated ex-
cellent results and improved biochemical outcomes when 
compared with EBRT monotherapy alone [7,8,9]. Ongoing 
developments with multi-modality imaging (US/CT/MRI) 
and adaptive treatment planning allows dose distributions 
to be calculated and updated in real time based on the clin-
ical requirements [10]. Despite this, the use of brachythera-
py across the world has been in decline over the last decade 
possibly due to broadening surgical practice, improved 
convenience of hypo-fractionated EBRT, and fewer resi-
dents in brachytherapy training programs [1,11,12]. 
The aim of this survey is to document the current 
prostate brachytherapy practice across UK and Ireland as 
compared to the previous Royal College of Radiologist’s 
(RCR) Audit in 2012, where possible [13]. Further, we 
wished to assess the application of standards as set out 
in RCR guidance and other international publications on 
quality assurance [2,3,4,5,6]. 
Material and methods
Centers attending the UK & Ireland Prostate Bra-
chytherapy Conference (Belfast, 2017) were invited to 
complete (one response per department) an online survey 
(Survey Monkey™). 
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Sixty-three questions were grouped into six themed 
sections as follows: 
1. Centre’s experience and staffing. 
2. Consultant experience, clinical selection criteria and 
scheduling: number of implants per practicing con-
sultant (banded as < 25, 25-50, and > 50), clinical se-
lection demographics, treatment scheduling, and fol-
low-up arrangements. 
3. Number of cases treated in the preceding 3 years 
(banded into 0-15, 15-25, 25-50, and > 50).
4. LDR pre-implant technique: imaging/contouring, 
implant details, source strength, average number of 
seeds/needles, treatment planning (TP) objectives, 
and constraints. 
5. LDR post-implant technique: imaging/contouring, 
prostate D90, room monitoring, and seed loss. 
6. HDR implant technique: imaging/contouring, im-
plant type, image registration, prescription dose, TP 
objectives, achieved dosimetry (V100%), and in-vivo 
dosimetry. 
Responses were collated, and descriptive statistical 
analysis performed. 
Results 
Centre’s experience and staffing 
Eighteen (72%) of 25 invited centers responded with-
in the timeframe. Seventeen centers perform LDR perma-
nent seed implantation compared to 15 in 2012, and 7 can- 
ters perform HDR prostate implant compared to 3 in 
2012 [13]. Six centers perform both LDR and HDR im-
plants as opposed to 7 in 2012, and 1 center performs 
HDR implantation only. Twelve (of 17) centers perform-
ing LDR brachytherapy have more than 10 years’ experi-
ence, and 5 (of 7) centers carrying out HDR implantation 
have more than 5 years’ experience. One center has less 
than 1-year HDR brachytherapy experience, whilst 2 cen-
ters have over 15 years’ experience. 
The RCR’s quality assurance (QA) practice guide-
lines for LDR permanent seed brachytherapy recommend 
a minimum of 2 radiation oncologists and 2 medical phys-
ics experts (MPE) on each brachytherapy team to ‘ensure 
service resilience’ [6]. Table 1 shows the current reported 
staffing levels. Thirteen (76%) centers have 2 or more im-
planting consultants, and 15 (88%) centers have 2 or more 
medical physics experts as opposed to 25 centers in 2012 
that had 2 or more clinical oncologists and MPEs [13]. 
Clinical and patient selection criteria 
Number of implants per consultant (2016) 
RCR guidelines recommend a minimum workload of 
25 cases (LDR + HDR) per clinical oncologist (CO) per 
year [6]. As shown in Table 2, 39% of centers reported 
that their leading consultants performed < 25 cases in the 
year 2016. Similarly, 38% and 50% centers reported that 
their 2nd and 3rd consultants have performed < 25 cases in 
2016, respectively. 
Treatment scheduling 
Twelve centers perform LDR combination therapy 
with 7 centers performing EBRT pre- and 5 performing 
EBRT post-brachytherapy. Of the 7 centers performing 
HDR combination therapy, 5 centers perform the HDR 
implant pre- and 2 centers carry out the HDR implant 
post-EBRT. 
Table 1. Brachytherapy staff numbers in UK and Ireland 2017 
Staff member No of respondents 
(total n = 18) 
Number of staff per center (whole time equivalent) 
1 2 3 > 3
Implanting consultants 18 5 7 4 2
Medical physics expert 18 3 9 5 1
Clinical scientist 16 0 5 6 5
Therapy radiographers 13 2 2 5 4
Physics trainees 15 8 3 2 2
Clinical trainees 6 4 1 0 1
UK – United Kingdom 
Table 2. Number of implants (low- + high-dose-rate) performed by each consultant (2016)
Staff No of respondents  
(total n = 18) 
Number of implants performed in the year 2016 
< 25 > 25-50 > 50
Consultant 1 18 7 7 4
Consultant 2 13 5 5 3
Consultant 3 6 3 2 1
LDR – low-dose-rate, HDR – high-dose-rate 
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Patient selection criteria for low-dose-rate prostate 
monotherapy 
The responses from centers on patient selection and 
criteria for LDR prostate monotherapy based on various 
factors are reflected in Table 3. Hormonal manipulation 
along with LDR treatments was used in 56% of centers in 
selected cases for either cyto-reduction prior to implant 
or as an adjuvant therapy for tumor management. Cur-
rent data is compared to previous published surveys. 
Clinical follow-up 
Clinical follow-up post-therapy is performed by on-
cology in 9 centers, shared care in 6 centers, and 1 center 
offering radiographer led follow-up alone. 
Number of cases treated in 2014-2016 
The number of cases treated during 2014-2016 is pre-
sented in Table 4, collected using banded groups: < 15 cases, 
Table 3. Clinical selection criteria for low-dose-rate prostate monotherapy – comparison of current survey 
with previous American Brachytherapy Society Surveys (1998 and 2012)
Criteria Prestidge et al. [14] Buyyounouski et al. [15] Current study
Respondents (%) Respondents (%) Respondents (%)
Gleason score; number of respondents                (n = 35) (n = 63) (n = 17)
6 12 (37) 17 (27) –
7 12 (37) 40 (63) 15 (88)
8 5 (14) 5 (8) 1 (6)
9 6 (17) 1 (2) 1 (6)
Maximum T stage; number of respondents (n = 35) (n = 60) (n = 17)
T1 2 (6) 5 (8) –
T2 31 (88) 53 (89) 15 (88)
T3A 2 (6) 2 (3) 2 (12)
Maximum prostate size in cc;  
number of respondents
(n = 35) (n = 59) (n = 15)
30/40 3 (9)/5 (14) –/4 (7) –
50 11 (31) 6 (10) 4 (27)
60 13 (37) 31 (53) 7 (46)
> 60 3 (9) 18 (30) 4 (27)
Maximum PSA (n = 35) (n = 59) (n = 17)
< 10 11 (31) 23 (39) 2 (12)
< 15 10 (29) 20 (34) 8 (47)
< 20 8 (23) 15 (25) 6 (35)
> 20 5 (14) 1 (2) 1 (6)
Previous TURP (n = 35) (n = 63) (n = 15)
Not a contradiction/not considered 12 (34) 8 (12) 5 (33)
Relative contradiction 19 (54) 52 (83) 6 (40)
Absolute contradiction 4 (11) 3 (5) 4 (27)
Hormonal manipulation (n = 35) (n = 0) (n = 16)
Yes 94% – 9 (56)
No – 7 (44)
PSA – prostate specific antigen, TURP – transurethral resection of the prostate, cc – cubic centimeter 
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15-35 cases, 35-50 cases, 50-75 cases, and > 75 cases per 
year. 
Low-dose-rate pre-implant technique 
Implant type and prescription dose 
The majority (14 of 17 centers) perform LDR 
brachytherapy as a ‘real-time’ implant, and 3 centers per-
form a ‘two-step procedure’. All 17 centers use 125I seeds, 
and 1 center also uses 103Pd and 131Cs. A prescription dose 
of 145 Gy for LDR monotherapy is used in 13 (76%) centers 
compared with 95% in the 2012 audit [13]. Four centers 
use a prescription dose of 160 Gy. For LDR combination 
with EBRT, the prescription dose was 110 Gy in 100% of 
centers in 2012. However, in 2014-2016 it is reported as: in 
8 centers – 110 Gy, 2 centers – 106 Gy, 2 centers – 107 Gy, 
1 center – 115 Gy, and 1 center did not specify. 
Imaging and contouring 
The most common imaging modality is ultrasound 
(USS), used by 65% of centers for the pre-treatment vol-
Table 4. Number of cases treated between 2014 and 2016 
Techniques Respondents 
(total n = 18)
No of cases treated 
< 15 > 15-35 > 35-50 > 50-75 > 75
LDR monotherapy 
2014 17 1 6 2 6 2 
2015 17 1 6 3 4 3 
2016 17 5 2 4 5 1 
LDR boost + EBRT 
2014 7 – 6 – 1 –
2015 8 – 6 – 2 –
2016 8 – 8 – – –
LDR focal 
2014 1 1 – – – –
2015 1 1 – – – –
2016 1 1 – – – –
LDR salvage 
2014 2 2 – – – –
2015 4 4 – – – –
2016 5 5 – – – –
HDR boost 
2014 5 1 – – – 4 
2015 5 1 – – – 4 
2016 6 2 – – 2 2 
HDR mono 
2014 4 3 – 1 – –
2015 5 2 2 – 1 –
2016 6 4 1 – 1 –
HDR salvage 
2014 1 1 – – – –
2015 3 3 – – – –
2016 3 3 – – – –
LDR – low-dose-rate, HDR – high-dose-rate, EBRT – external beam radiation therapy 
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ume study. Multiple modality imaging is used in 4 cen-
ters and 1 center uses MRI. Pre-treatment contouring is 
performed by the oncologists (38%), radiologists (13%), 
radiographers (13%), urologists (19%), and others (19%), 
which includes physicists. Image registration/fusion is 
used in 3 centers. 
Treatment planning, seed placement, and source 
strength 
Treatment planning (TP) is carried out by a physicist 
or dosimetrist in all the centers. During the implant, the 
ultrasound is operated by the oncologist (n = 9) or urolo-
gist (n = 9), radiologist (n = 5) or physicist (n = 1). 
The majority of centers (n = 10) use stranded seed 
placement, 1 center uses a variation of all 4 placements 
including stranded, preloaded, loose, and Mick applica-
tors. Seven centers use loose seeds for calibration, 5 use 
strands, and 1 center uses both. Most centers use a refer-
ence air kerma rate (RAKR) of 0.5-0.6 U (n = 12) or 0.4-0.5 U 
(n = 11), and 1 center uses a RAKR of > 0.7 U. 
The mean number of needles used are 23 (± 5) and 
mean number of seeds are 72 (± 9) per LDR monotherapy 
implant, although this is RAKR dependent. The average 
number of needles and seeds per unit volume (cc) is 0.85 
(± 0.5) and 1.9 (± 0.5), respectively. 
Planning objectives and independent dose calculation 
verification 
The objective for prostate V100% is ≥ 99% at 7 centers, 
> 98% at 2, and > 95% at 8 centers. Seven centers require 
a clinical target volume (CTV) V100% of > 95%. Fifteen 
centers report V150% to the prostate and 8 centers report 
V150% to a CTV. D30% to the urethra is reported by 11 cen-
ters and the majority aim for < 130% of prescribed dose. 
D10% is reported by 8 centers, with the majority aiming 
for < 150%. The majority of centers (n = 11) report a limit 
for D2cc rectum as < 145 Gy. A variety of constraints for 
prostate, CTV, urethra, and rectum were applied during 
treatment planning as shown in Table 5. 
Post-implant dosimetry 
Post-implant CT scans are routinely performed in all 
centers compared with 77% in 2012 [13]. Ninety-four per-
cent (n = 16) perform the scan 4-6 weeks later, and one 
center on day 0/day 1. Similar to the pre-implant con-
touring, the oncologist performs the majority (n = 10) of 
the post-implant contouring followed by radiographers 
(n = 4), and others such as the radiologist, physicist, and 
dosimetrist (n = 3). Thirteen centers perform routine cal-
culation of the CT/ultrasound volume. The median CT/
US volume ratios were > 0.9 ≤ 1.0 (n = 4), > 1.0 ≤ 1.1 (n = 7), 
and > 1.1 (n = 2). Three centers routinely perform image 
registration or fusion in post-implant dosimetry, and sec-
tor analysis is performed by 4 centers. 
The average prostate D90 (Gy) achieved over the pe-
riod 2014-2016 is displayed in Table 6. Sixty-nine per-
cent of the centers reported average D90 > 145 Gy in the 
years 2014 and 2015, whereas 63% of the centers achieved 
> 145 Gy in 2016. 






Number of  
respondents 
Prostate 
V100% (n = 17) > 99.8% 1 
> 99.5% 1 
> 99% 5 
> 98% 2 
> 95% 8 
CTV 
V100% (n = 9) > 95% 7 
Don’t grow CTV 1 
CTV = prostate 1 
Prostate 
V150% (n = 15) < 70% 2 
< 65% 2 
< 60% 2 
> 55-65% 1 
55-60% 1 
< 55% 1 
< 50% 1 
40-65% 1 
CTV 
V150% (n = 8) < 70% 1 
< 65% 1 
< 50% 4 
Don’t grow CTV 1 
CTV = Prostate 1 
Urethra 
D30% (n = 11) < 130% 5 
< 150% 3 
< 181 Gy 2 
< 240 Gy 1 
D10% (n = 8) < 150% 7 
< 165% 1 
V150% (n = 1) = 0 cc 1 
V140% (n = 1) < 5% of the volume 1 
Rectum 
V100% (n = 6) < 5% 2 
< 0.4 cc 1 
< 0.9 cc 1 
< 1 cc 1 
< 1.3 cc 1 
D2cc (n = 10) < 145 Gy 10 
D0.1cc (n = 3) < 200 Gy 3 
V69% (n = 1) < 2.6 cc 1 
V91% (n = 1) < 1 cc 1 
CTV – clinical target volume, Vx% – volume receiving x% of the prescribed dose, 
Dxcc – dose received by x cc of the volume, Dx% – dose received by x% of the 
volume, Gy – Gray, cc – cubic centimeter 
Journal of Contemporary Brachytherapy (2018/volume 10/number 3)
UK & Ireland Prostate Brachytherapy Practice Survey 2014-2016 243
Table 6. Post-implant average D90 for the three-year period (2014-2016) 
Year No of respondents Post-implant D90
< 145 Gy > 145-155 Gy > 155-170 Gy > 170 Gy
2014 16 5 (31%) 3 (19%) 6 (37%) 2 (13%)
2015 16 5 (31%) 3 (19%) 7 (44%) 1 (6%)
2016 16 6 (37%) 2 (13%) 4 (25%) 4 (25%)
D90 – dose to 90% of the prostate volume, Gy – Gray 
Table 7. 2014-2016 reported standards compared to the 2012 RCR Survey Standards 
RCR standard  
recommendations 





1 Each department should carry 
out at least 25 cases/year [15] 
100% 100% 71% centers treated > 15 cases  
of LDR in 2016 
2 Each CO should carry out  
at least 5 cases/year [15] 
100% 95% Not recorded in current survey 
but 59% CO carry out at least  
25 cases/year 
3 Dose prescribed for LDR 
should be 145 Gy  
for monotherapy  
and 110 Gy for boosts [5,6] 
100% 95% – monotherapy 
100% – boost 
76% – 145 Gy monotherapy 
24% – 160 Gy monotherapy 
64% – 110 Gy as boost 





5 PID should be carried out  
at day 30 [17]
90% 32% 94% – 4-6 weeks 
6% – day 0/1 
6 Dose to OAR should be  
assessed [16,17] 
90% 95% – 1+ organ 
32% – 2+ organs 
88% reported tolerances  
for 2 organs 
RCR – Royal College of Radiologists, CO – clinical oncologist, LDR – low-dose-rate, PID – post-implant dosimetry, OAR – organs at risk, Gy – Gray 
Post-procedure radiation protection room monitor-
ing is usually performed by a nurse or physicist. Aver-
age seed loss, whereby seeds implanted were not seen on 
post-implant dosimetry, was < 3 per year in the majority 
of centers, 2 centers had seed loss > 3, but < 10 seeds per 
year based on number of seeds implanted versus number 
identified on the post-implant CT. 
High-dose-rate brachytherapy technique 
Of the 6 centers performing HDR monotherapy, 5 cen-
ters prescribe 19 Gy to 100% isodose volume and ensure 
that 95% of planning target volume (PTV) is encompassed 
by the 100% isodose, whereas 1 center prescribes 19 Gy to 
90% of prostate volume. The definition of CTV was not 
acquired in this survey, although the GEC/ESTRO rec-
ommendations define CTV as the prostate capsule plus 
any macroscopic extracapsular disease or seminal vesi-
cle involvement expanded by 3 mm, constrained by the 
anterior rectal wall and bladder base [5]. Seven centers 
report HDR boost doses of 15 Gy; 5 centers prescribing 
to 100% isodose volume and 2 centers to 90% prostate 
volume. Salvage therapy is performed by 4 centers, with 
2 centers prescribing 15 Gy to 100% isodose volume, and 
the others prescribing 19 Gy to 100% isodose volume or 
90% of prostate volume. 
Although none of the centers performed focal therapy 
during the 3-year period, 1 center suggested that the pre-
scription dose would utilize a focal boost of 21 Gy to the 
dominant lesion and 15 Gy to the non-dominant prostatic 
PTV (although definition of same not provided). Details 
of cases numbers are detailed in Table 4. 
In all but 1 center, the oncologist performs the pre- 
treatment contouring, with the other done by the ra-
diologist. Ultrasound guidance is used in all centers for 
implants and routine QA is performed in all centers; 
5 centers use metal needles and 2 use plastic needles, and 
most centers report an average of 15-20 needles per implant. 
Three centers utilize image registration (US and MRI). 
The average percentage of the target volume receiv-
ing 100% of the dose (V100%) is 95-98% in 4 centers, > 95% 
in 1 center, and 98-100% in 2 centers. Independent dose 
calculation verification is carried out in all centers. One 
center performs in vivo dosimetry measurements using 
MOSFET detectors. 
Comparison with 2012 RCR Prostate 
Brachytherapy Audit 
Table 7 includes the current standards, where com-
parable to the standards achieved in the 2012 Audit [13]. 
Discussion and conclusion 
Whilst the current survey had fewer responses than 
the RCR 2012 audit, we believe it is an accurate represen-
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tation of prostate brachytherapy practice in the UK and 
Ireland, documenting the evolution in techniques and 
case numbers over the preceding 3 years. There is a clear 
focus on maintaining high quality implants, as evidenced 
by the reported D90’s and the universal use of the 3 key 
RCR QA markers in LDR of D90, CT/US volume ratio, 
and V100 across responding centers. 
We note a number of centers reporting a reduction 
in LDR cases from 2014 to 2016 either as monotherapy 
or as combination therapy [1,2,3,4,5,6,7,8,9,10,13,18,19]. 
ASCENDE RT showed that men treated with LDR boost 
were twice as likely to be biochemically failure-free when 
compared to EBRT alone, was only presented in February 
2015 at GU ASCO, and thus may not have impacted prac-
tice immediately [20]. However, it is also possible that 
the companion paper on toxicity could have negated the 
impact of this important study [21]. The continuous im-
provement in planning technology and review of expan-
sion margins may help to reduce the potential of long-
term urinary toxicity in combination cases, whilst hoping 
to maintain the biochemical benefit over EBRT alone. 
The number of LDR boost treatments overall is mod-
est. Robotic radical prostatectomies, improving conve-
nience of hypo-fractionated EBRT for low- to intermedi-
ate-risk disease, following the CHHiP trial publication, 
and research interests in stereotactic radiotherapy are 
competing treatment options that may have impacted on 
referral practice [22,23,24]. 
HDR brachytherapy boost numbers appear to be in-
creasing with more centers offering this modality in the 
last 5 years. Whilst the procedure time is longer, the ra-
diobiological advantages, improved USS-based planning 
software, reduced reliance on operator skill, and poten-
tial consumable cost saving may have contributed to the 
limited impact of ASCENDE RT on the number of LDR 
boosts being performed. This cohort of high tier interme-
diate and high-risk cases are perhaps now directed to-
ward HDR combined with EBRT with its own supporting 
evidence base [25,26]. 
The number of implants performed by individu-
al consultants is noteworthy. Firstly, based on the RCR 
guidance, consultants are encouraged to perform at least 
25 cases per year, our survey shows that 41% of implant-
ing consultants in 2016 carried out less than this num-
ber. This may be due to the apparent fall in LDR cases 
reported by some centers in our survey or to an increas-
ing number of implanting consultants individually per-
forming fewer cases. The 2012 Audit reported that 100% 
of centers performed > 25 cases per year, although spe-
cific numbers per consultant was not documented but 
95% of consultants performed at least 5 implants per year 
[12]. Secondly, the RCR guidelines suggest that in order 
to mentor a trainee in brachytherapy, the mentor should 
be performing > 100 implants over the preceding 3-year 
period. Our survey therefore suggests that the potential 
mentor cohort based on this guidance is modest. Trainees 
may therefore have limited exposure to brachytherapy, 
as has been reported in the US [26]. Reduced trainee ex-
perience and exposure to prostate brachytherapy could 
shrink the collegiate knowledge of patient selection and 
the procedure, leading to a reduced referral rate. 
This survey was limited by the lower number of re-
sponses received from institutions (n = 18) than the previ-
ous 2012 RCR audit (n = 29). It is unclear if this represents 
failure to respond or if there has been a true reduction in 
the number of centers offering brachytherapy and consol-
idating their cases to higher volume centers. This could 
be answered by repeating the RCR audit using the same 
methodology as in 2012 and adapting our survey ques-
tionnaire. We recognize that the information gained in 
this survey would have been enhanced by asking for the 
absolute number of cases per year, their referral sources, 
and the specific prescription points used for the dosim-
etric variables, including target volume definitions and 
expansion margins used. 
Pleasingly, our survey shows that all brachytherapy 
teams are continually reviewing and assessing implant 
quality by performing post-implant dosimetry in 100% 
of cases, and as an adaptive process may identify and 
adjust parameters for their center that maintain and im-
prove dosimetric quality, biochemical, and toxicity out-
comes. 
For men with localized prostate cancer, LDR/HDR 
monotherapy or EBRT combined with LDR/HDR boost 
provides excellent biochemical outcomes [1], and sev-
eral studies have reported superior outcomes, reduced 
toxicities, and excellent quality of life at a low-cost from 
either form of brachytherapy when compared to other 
treatments. Prostate brachytherapy offers suitable men 
an outstanding opportunity to achieve a high-dose, pre-
cisely targeted, and convenient treatment with excellent 
biochemical outcomes [2,3,7,27,28,29,30,31,32,33,34,35,36]. 
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